Search
LV-SMENP Vaccine
go.drugbank.com/drugs/DB15804ExperimentalLV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which
Urelumab
go.drugbank.com/drugs/DB12077InvestigationalThe antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with
Totrombopag
go.drugbank.com/drugs/DB05930InvestigationalThis drug is developed by GlaxoSmithKline and used to treat Thrombocytopenia.Thrombocytopenia (decreased platelet count) is a common side effect of many chemotherapies and can lead to uncontrolled bleeding
Alphameprodine
go.drugbank.com/drugs/DB01499ExperimentalIllicitAlphameprodine is an opioid analgesic classified by the United States Drug Enforcement Administration under Schedule I of illegal substances.
Betameprodine
go.drugbank.com/drugs/DB01552ExperimentalIllicitBetameprodine is an opioid analgesic classified by the United States Drug Enforcement Administration under Schedule I of illegal substances.
Osanetant
go.drugbank.com/drugs/DB04872InvestigationalDeveloped by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System
1-Deoxy-D-xylulose 5-phosphate
go.drugbank.com/drugs/DB02496ExperimentalThese are carbohydrate derivatives containing a pentose substituted by one or more phosphate groups.
Tefidsogene civaparvovec
go.drugbank.com/drugs/DB16789InvestigationalDeveloped by Sangamo Therapeutics, tefidsogene civaparvovec is being investigated in mucopolysaccharidosis type II.[A258789, L45949]
Viral Macrophage-Inflammatory Protein
go.drugbank.com/drugs/DB15748ExperimentalViral macrophage inflammatory protein-II (vMIP) is a highly basic protein and human chemokine analog encoded by human herpesvirus-8.